This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT07720271 |
|---|---|
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Novo Nordisk A/S |
| Enrollment | 950 participants |
| Design | Interventional, Randomized, Parallel, Masking: Quadruple |
| Conditions | Overweight; Obesity |
| Interventions | zenagamtide; Placebo |
| Start | Aug 31, 2026 |
| Primary completion | Jun 27, 2028 |
| Study completion | Aug 22, 2028 |
| Results posted | Not yet |
| Registry last updated | Sep 28, 2026 |
Compounds on this site that cite this trial
What the registry says the trial is about
The purpose of this clinical study is to find out if zenagamtide is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as oral tablets once a day. Participants will either get zenagamtide (the treatment being tested) or Placebo (treatment that has no active medicine in it). Which treatment participants get is decided by chance.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Relative change in body weight | From baseline (week 0) to (week 76) |
2 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Nov 18, 2026. See the trial changes feed for what has changed recently.
More from Novo Nordisk A/S
- Cagrilintide: Phase 3 Trial in Obesity (NCT07220642)
- Cagrilintide: Phase 3 Trial (NCT07220759)
- Cagrilintide and Semaglutide: Phase 3 Trial (NCT06323161)
- Cagrilintide, Semaglutide and Tirzepatide: Phase 3 (NCT06131437)
Research area: Metabolic and incretin. Every registered trial we follow is in the clinical trial tracker, and the labels used on this page are explained in our evidence standards.